Price
$9.9
Increased by +1.85%
Dollar Volume
2.31 M
ADR%
7.05
Earnings Report Date (estimate)
Mar 14, 23 (-0.19)
Market Cap.
418.64 M
Shares Float
34.42 M
Shares Outstanding
42.29 M
Beta
0.52
Price / Earnings
-12.92
BPR
66.98
20D Range
9.20 11.32
50D Range
9.20 11.35
200D Range
6.89 13.66
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 -0.01
Increased by +88.89%
-0.12
Increased by +91.67%
Aug 3, 22 -0.06
Increased by +33.33%
-0.14
Increased by +57.14%
May 4, 22 -0.20
Decreased by -150.00%
-0.15
Decreased by -33.33%
Feb 22, 22 -0.08
Increased by 0.00%
-0.13
Increased by +38.46%
Nov 3, 21 -0.09
Decreased by -325.00%
-0.14
Increased by +35.71%
Aug 4, 21 -0.09
Increased by +40.00%
-0.13
Increased by +30.77%
May 5, 21 -0.08
Increased by +57.89%
-0.16
Increased by +50.00%
Feb 22, 21 -0.08
Increased by +20.00%
-0.12
Increased by +33.33%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 36.96 M
Increased by +18.44%
-4.32 M
Increased by +39.53%
Decreased by -11.68%
Increased by +48.95%
Jun 30, 22 34.45 M
Increased by +2.60%
-7.74 M
Increased by +2.00%
Decreased by -22.46%
Increased by +4.49%
Mar 31, 22 31.01 M
Decreased by -0.10%
-11.47 M
Decreased by -72.30%
Decreased by -37.01%
Decreased by -72.46%
Dec 31, 21 31.54 M
Decreased by -2.95%
-5.29 M
Increased by +12.05%
Decreased by -16.76%
Increased by +9.37%
Sep 30, 21 31.20 M
Decreased by -6.65%
-7.14 M
Decreased by -382.83%
Decreased by -22.88%
Decreased by -417.24%
Jun 30, 21 33.58 M
Increased by +51.84%
-7.90 M
Increased by +2.55%
Decreased by -23.52%
Increased by +35.82%
Mar 31, 21 31.04 M
Increased by +27.93%
-6.66 M
Increased by +18.70%
Decreased by -21.46%
Increased by +36.45%
Dec 31, 20 32.49 M
Increased by +15.39%
-6.01 M
Increased by +14.61%
Decreased by -18.50%
Increased by +25.99%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.